A Chinese chemical company and four of its employees have been indicted by U.S. authorities for allegedly manufacturing and distributing fentanyl precursors and xylazine, a sedative known as the “zombie drug.” The U.S. Department of Justice announced charges against Hubei Aoks Bio-Tech Co. Ltd., based in Wuhan, China, for its alleged role in fueling the fentanyl crisis in the United States.
Details of the Indictment
The 13-count federal indictment accuses the company of selling large quantities of fentanyl precursors to U.S. customers from 2016 to 2023. These chemicals were often mislabeled as innocuous items like furniture parts to avoid detection. The company is also charged with selling xylazine, an animal tranquilizer that has been linked to severe flesh-rotting effects in humans.
Individuals Charged and Potential Penalties
Among those indicted are the company’s director, Xuening Gao, and three senior employees. The charges include conspiracy to manufacture and distribute fentanyl and introducing misbranded drugs into interstate commerce. If convicted, the defendants face a minimum of 10 years to life in prison.
International and Domestic Efforts to Combat Drug Crisis
U.S. Attorney Martin Estrada emphasized the importance of holding accountable those who contribute to the synthetic drug crisis. The case, investigated by multiple U.S. agencies including the DEA and FDA, highlights ongoing efforts to combat the international drug trade. Chinese authorities have reportedly arrested the defendants and dissolved the company following their own investigation.
